JP2001508449A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508449A5
JP2001508449A5 JP1998531199A JP53119998A JP2001508449A5 JP 2001508449 A5 JP2001508449 A5 JP 2001508449A5 JP 1998531199 A JP1998531199 A JP 1998531199A JP 53119998 A JP53119998 A JP 53119998A JP 2001508449 A5 JP2001508449 A5 JP 2001508449A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998531199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508449A (ja
JP4551502B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/000532 external-priority patent/WO1998030545A1/en
Publication of JP2001508449A publication Critical patent/JP2001508449A/ja
Publication of JP2001508449A5 publication Critical patent/JP2001508449A5/ja
Application granted granted Critical
Publication of JP4551502B2 publication Critical patent/JP4551502B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53119998A 1997-01-06 1998-01-06 病原体不活化のための脆い化合物 Expired - Lifetime JP4551502B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US08/779,885 1997-01-06
US77983097A 1997-01-07 1997-01-07
US08/779,830 1997-01-07
US4369697P 1997-04-15 1997-04-15
US60/043,696 1997-04-15
PCT/US1998/000532 WO1998030545A1 (en) 1997-01-06 1998-01-06 Frangible compounds for pathogen inactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009286996A Division JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Publications (3)

Publication Number Publication Date
JP2001508449A JP2001508449A (ja) 2001-06-26
JP2001508449A5 true JP2001508449A5 (enExample) 2005-09-08
JP4551502B2 JP4551502B2 (ja) 2010-09-29

Family

ID=27366374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53119998A Expired - Lifetime JP4551502B2 (ja) 1997-01-06 1998-01-06 病原体不活化のための脆い化合物
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Country Status (9)

Country Link
EP (1) EP1021414B1 (enExample)
JP (2) JP4551502B2 (enExample)
CN (2) CN1248245B (enExample)
AT (1) ATE243198T1 (enExample)
AU (1) AU744089C (enExample)
CA (1) CA2276532C (enExample)
DE (1) DE69815703T2 (enExample)
ES (1) ES2196530T3 (enExample)
WO (1) WO1998030545A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276532C (en) * 1997-01-06 2008-06-17 Cerus Corporation Frangible compounds for pathogen inactivation
CN1203900C (zh) 1998-01-06 2005-06-01 塞鲁斯公司 用于淬灭生物材料中病原体灭活剂的方法
JP2002517435A (ja) 1998-06-11 2002-06-18 シーラス コーポレイション 動脈平滑筋細胞の増殖阻害のためのアルキル化化合物の使用
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
CA2434256A1 (en) * 2000-12-21 2003-07-31 David Cook Methods for inactivation of pathogens in biological materials
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CA2585621C (en) 2004-10-29 2015-12-15 Cerus Corporation Improved quenching methods for red blood cell inactivation process
KR101896430B1 (ko) 2008-04-09 2018-09-10 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
EA201890149A1 (ru) 2015-06-26 2018-07-31 Сирус Корпорейшн Композиции криопреципитатов и способы их получения
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017382449B2 (en) 2016-12-23 2024-10-24 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
BR112019018273A2 (pt) 2017-03-03 2020-07-14 Cerus Corporation kits e métodos para preparação de composições de plaquetas inativadas por patógenos
TWI821233B (zh) 2017-12-29 2023-11-11 美商西勒斯股份有限公司 用於處理生物流體之方法、藉由該方法製備之病原體去活生物流體、及用於處理生物流體之系統
CA3143213A1 (en) 2019-06-22 2020-12-30 Cerus Corporation Biological fluid treatment systems
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020090A1 (en) * 1993-03-17 1994-09-15 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
AU722811B2 (en) * 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents
CA2276532C (en) * 1997-01-06 2008-06-17 Cerus Corporation Frangible compounds for pathogen inactivation

Similar Documents

Publication Publication Date Title
JP2002511952A5 (enExample)
JP2000507042A5 (enExample)
JP2000509635A5 (enExample)
JP2000509637A5 (enExample)
JP2000509942A5 (enExample)
JP2001511042A5 (enExample)
JP2001524256A5 (enExample)
JP2002514283A5 (enExample)
JP2002509550A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000508022A5 (enExample)
JP2001508449A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2002511894A5 (enExample)
JP2000510969A5 (enExample)
JP2000508102A5 (enExample)
JP2001517990A5 (enExample)
JP2001511327A5 (enExample)
JP2000509520A5 (enExample)